Publicacións en colaboración con investigadores/as de Fundación Jiménez Díaz (30)

2024

  1. Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry

    Archivos de Bronconeumologia, Vol. 60, pp. S38-S45

  2. Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry

    Lung Cancer, Vol. 190

  3. QIM24-189: Molecular Tumor Boards Excellence. Phase 1-State of the Art in Spain

    Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25

2023

  1. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

2022

  1. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

    BMC Cancer, Vol. 22, Núm. 1

2021

  1. Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications

    JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169

  2. Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain

    Revista de la Sociedad Espanola del Dolor, Vol. 28, pp. 19-26

  3. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment

    Molecular Oncology, Vol. 15, Núm. 9, pp. 2363-2376

  4. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

    BMC Cancer, Vol. 21, Núm. 1

  5. Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study

    Frontiers in Oncology, Vol. 11

2020

  1. Development of a multicriteria decision analysis framework for evaluating and positioning oncologic treatments in clinical practice

    Journal of Oncology Practice

  2. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation

    Cancer Epidemiology, Vol. 67

2019

  1. Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP)

    Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 380-390

  2. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

    Journal of Thoracic Oncology, Vol. 14, Núm. 2, pp. 304-310

  3. Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)

    Translational Lung Cancer Research, Vol. 8, Núm. 4, pp. 461-475

  4. Working towards a consensus on the oncological approach of breakthrough pain: A Delphi survey of Spanish experts

    Journal of Pain Research, Vol. 12, pp. 2349-2358

2018

  1. Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii611-viii612

  2. Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii612

  3. Clinical utility of complex multi-platform profiling in metastatic cancer patients

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii480

  4. First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii535-viii536